Monopar Therapeutics Inc (NASDAQ: MNPR) is 243.33% higher on its value in year-to-date trading and has touched a low of $1.37 and a high of $8.65 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MNPR stock was last observed hovering at around $5.17 in the last trading session, with the day’s gains setting it 0.67%.
Currently trading at $5.84, the stock is 74.35% and 88.43% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing 12.96% at the moment leaves the stock 86.72% off its SMA200. MNPR registered 102.15% gain for a year compared to 6-month loss of 58.48%. The firm has a 50-day simple moving average (SMA 50) of $3.145 and a 200-day simple moving average (SMA200) of $3.146925.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 143.33% gain in the last 1 month and extending the period to 3 months gives it a 57.31%, and is 29.78% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.16% over the week and 13.61% over the month.
Monopar Therapeutics Inc (MNPR) has around 10 employees, a market worth around $20.56M and $0.00M in sales. Distance from 52-week low is 326.43% and -32.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-116.98%).
The EPS is expected to shrink by -140.44% this year
12.0 institutions hold shares in Monopar Therapeutics Inc (MNPR), with institutional investors hold 5.09% of the company’s shares. The shares outstanding are 2.98M, and float is at 1.77M with Short Float at 36.86%. Institutions hold 2.38% of the Float.
The top institutional shareholder in the company is MILLENNIUM MANAGEMENT LLC with over 0.19 million shares valued at $0.15 million. The investor’s holdings represent 1.2159 of the MNPR Shares outstanding. As of 2024-06-30, the second largest holder is GEODE CAPITAL MANAGEMENT, LLC with 60036.0 shares valued at $44906.0 to account for 0.3757 of the shares outstanding. The other top investors are TWO SIGMA SECURITIES, LLC which holds 47058.0 shares representing 0.2945 and valued at over $34357.0, while VANGUARD GROUP INC holds 0.2827 of the shares totaling 45167.0 with a market value of $32976.0.
Monopar Therapeutics Inc (MNPR) Insider Activity
The most recent transaction is an insider purchase by Cittadine Andrew, the company’s Chief Operating Officer. SEC filings show that Cittadine Andrew bought 20,508 shares of the company’s common stock on Jun 20 ’24 at a price of $0.74 per share for a total of $15254.0. Following the purchase, the insider now owns 0.19 million shares.
Monopar Therapeutics Inc disclosed in a document filed with the SEC on Jun 18 ’24 that Cittadine Andrew (Chief Operating Officer) bought a total of 12,000 shares of the company’s common stock. The trade occurred on Jun 18 ’24 and was made at $0.86 per share for $10320.0. Following the transaction, the insider now directly holds 0.17 million shares of the MNPR stock.
Still, SEC filings show that on Jun 14 ’24, Cittadine Andrew (Chief Operating Officer) acquired 12,000 shares at an average price of $0.93 for $11176.0. The insider now directly holds 141,624 shares of Monopar Therapeutics Inc (MNPR).
